Bacterial Spectrum and Antimicrobial Susceptibility Pattern of Bloodstream Infections in Children with Febrile Neutropenia: Experience of Single Center in Southeast of Turkey

Indian Journal of Microbiology

Volumn 52, Issue 2, 2012, Pages 203-208

  Aslan, Selda ^a   Citak, Elvan Caglar ^b   Yis, Reyhan ^a   Degirmenci, Suleyman ^a   Arman, Dilek ^c  

^a Gaziantep Children Hospital   (Turkey)

^b MERSIN UNIVERSITY   (Turkey)

^c GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Antibiotic susceptibility; Children; Febrile neutropenia

Indexed keywords

BACILLI (CLASS); BACTERIA (MICROORGANISMS); ENTEROCOCCUS; ENTEROCOCCUS FAECIUM; ENTEROCOCCUS HIRAE; ESCHERICHIA COLI; FUNGI; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEGIBACTERIA; POSIBACTERIA; PROTEUS (ENTEROBACTERIA); STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS;

EID: 84863189376     PISSN: 00468991     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12088-011-0210-6     Document Type: Article

References (35)

1. Klastersky J (1998) Science and pragmatism in the treatment and prevention of neutropenic infection. J Antimicrob Chemother 41: 13-24.
2. Akova M (2006) Emerging problem pathogens: a review of resistance patterns over time. Int J Infect Dis 10: S3-S8.
3. Clinical and Laboratory Standards Institute (2009) Performance standards for antimicrobial susceptibility testing. Nineteenth informational supplement. M100-S19. CLSI, Wayne, PA.
4. Zinner SH (1999) Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 29: 490-494.
5. Ramphal R (2004) Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated agents. Clin Infect Dis 39(suppl 1): S25-S31.
6. De Lalla F (1997) Antibiotic treatment of febrile episodes in neutropenic cancer patients. Drugs 53: 789-804.
7. Elting L, Rubenstein E, Rolston K, Bodey G (1997) Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 25: 247-259.
8. Ariffin H, Navaratnam P, Lin HP (2002) Surveillance study of bacteremic episodes in febrile neutropenic children. Int J Clin Pract 56: 237-240.
9. Paya E, Alvarez AM, Aviles C et al (2001) Causative agents of bloodstream infections in children with neoplasm, in 5 hospitals of Santiago. Rev Med Chil 129: 1297-1304.
10. Viscoli C, Castagnola E, Giacchino M et al (1999) Bloodstream infections in children with cancer: a multicentre surveillance study of the Italian Association of Pediatric Haematology and Oncology. Supportive Therapy Group-Infectious Diseases Section. Eur J Cancer 35: 770-774.
11. Calik N et al (2005) Epidemiology of bacterial infections and risk factors for mortality in cancer patients. In: Abstracts ICAAC, Washington DC, USA. K-1529.
12. Meropenem Study Group of Turkey, Akova M, Akan H (1999) Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics. Int J Antimicrob Agents 13: 15-19.
13. Denning DW et al (1997) Guidelines fort he investigation of invasive fungal infections in haematological malignancy and solid organ transplantation. Eur J Clin Microbiol Infect Dis 16: 424-436.
14. Oppenheim BA (1998) The changing pattern of infection in neutropenic patients. J Antimicrob Chemother 41(D): 7-11.
15. Viscoli C, Castagnola E (2002) Treatment of febrile neutropenia: what is new? Curr Opin Infect Dis 15: 377-382.
16. Edmond MB, Ober JF, Weinbaum DL et al (1995) Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 20: 1126-1133.
17. Mlynarczyk A, Mlynarczyk G, Luczak M (2002) Conjugative transfer of glycopeptide and macrolide resistant genes among enterococci and from Enterococcus faecalis to Staphylococcus aureus. Med Dosw Mikrobiol 54: 21-28.
18. Noble WC, Virani Z, Cree RG (1992) Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 72: 195-198.
19. Carratalá J, Alcaide F, Fernández Sevilla A et al (1995) Bacteremia due to viridans streptococci that are highly resistant to penicillin: increase among neutropenic patients with cancer. Clin Infect Dis 20: 1169-1173.
20. Borg MA, Scicluna E, de Kraker M, van de Sande-Bruinsma N, Tiemersma E, Gur D, Ben Redjeb S, Rasslan O, Elnassar Z, Benbachir M, Pieridou Bagatzouni D, Rahal K, Daoud Z, Grundmann H, Monen J (2006) Antibiotic resistance in the southeastern Mediterranean-preliminary results from the ARMed project. Euro Surveill 11: 164-167.
21. Celkan T, Diren S, Ozyilmaz I, Karaman S, Canbolat A, Ozkan A, Apak H, Yildiz I (2006) The growth rates, isolated agents and their antibiotic resistance in febrile neutropenic attacks between 2000-2004 years. ANKEM Dergisi 20: 4-9.
22. Kosack A, Riedel E, Kiehn TE, Small TN, Wexler LH, Dunkel IJ (2009) Vancomycin-resistant enterococcus in pediatric oncology patients: an analysis of potential consequences of colonization and infection. Pediatr Blood Cancer 52: 300-302.
23. Werner G, Coque TM, Hammerum AM, Hope R, Hryniewicz W, Johnson A, Klare I, Kristinsson KG, Leclercq R, Lester CH, Lillie M, Novais C, Olsson-Liljequist B, Peixe LV, Sadowy E, Simonsen GS, Top J, Vuopio-Varkila J, Willems RJ, Witte W, Woodford N (2008) Emergence and spread of vancomycin resistance among enterococci in Europe. Euro Surveill 13pii: 19046.
24. Schouten MA, Hoogkamp-Korstanje JA, Meis JF et al (2000) Prevalence of vancomycin-resistant enterococci in Europe. Eur J Clin Microbiol Infect Dis 19: 816-822.
25. Kilic A, Bedir O, Tunc T, Besirbellioglu B, Eyigun CP, Basustaoglu AC (2009) An outbreak of vanA genotype Enterococcus faecium in pediatric clinic of a training hospital. Mikrobiyol Bul 43: 365-372.
26. Ergani-Ozcan A, Naas T, Baysan BO, Ogunc D, Inan D, Colak D, Nordmann P (2008) Nosocomial outbreak of vancomycin-resistant Enterococcus faecium in a paediatric unit at a Turkish university hospital. J Antimicrob Chemother 61: 1033-1039.
27. Comert FB, Kulah C, Aktas E, Ozlu N, Celebi G (2007) First isolation of vancomycin-resistant enteroccoci and spread of a single clone in a university hospital in northwestern Turkey. Eur J Clin Microbiol Infect Dis 26: 57-61.
28. Kacmaz B, Aksoy A (2005) Antimicrobial resistance of enterococci in Turkey. Int J Antimicrob Agents 25: 535-538.
29. Rolston KV, Berkey P, Bodey GP et al (1992) A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 152: 283-291.
30. Yamamura D, Gucalp R, Carlisle P et al (1997) Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients. Antimicrob Agents Chemother 41: 1704-1708.
31. EORTC, Dornbusch K, King A, Legakis N (1998) Incidence of antibiotic resistance in blood and urine isolates from hospitalized patients. Report from a European collaborative study. European Study Group on Antibiotic Resistance (ESGAR). Scand J Infect Dis 30: 281-288.
32. Verbist L (1993) Epidemiology and sensitivity of 8625 ICU and haematology/oncology bacterial isolates in Europe. International Study Group. Scand J Infect Dis Suppl 91: 14-24.
33. NN-V. Usage of Antibacterial Agents and Occurrence of Antimicrobial Resistance in Norway. Tromsø/Oslo 2004, 2004.
34. Butt T, Afzal RK, Ahmad RN et al (2004) Bloodstream infections in febril neutropenic patients: bacterial spectrum and antimicrobial susceptibility pattern. J Ayub Med Coll Abbottabad 16: 18-22.
35. Ariffin H et al (2000) Ceftazidime resistant Klebsiella pneumoniae bloodstream infection in children with febrile neutropenia. Int J Infect Dis 4: 21-25.